Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Prostatic Neoplasms 2966Carcinoma, Renal Cell 882Urinary Bladder Neoplasms 711Kidney Neoplasms 457Breast Neoplasms 408Neoplasms 390Neoplasm Metastasis 229Carcinoma, Non-Small-Cell Lung 229Lung Neoplasms 216Ovarian Neoplasms 211Colorectal Neoplasms 204Melanoma 195Carcinoma, Transitional Cell 190Testicular Neoplasms 171Pancreatic Neoplasms 142Sarcoma 129Head and Neck Neoplasms 121Colonic Neoplasms 120Wilms Tumor 119Uterine Cervical Neoplasms 116Stomach Neoplasms 98Neuroblastoma 90Multiple Myeloma 88Lymphoma, Non-Hodgkin 86Esophageal Neoplasms 86Lymphoma 83Carcinoma, Hepatocellular 81Carcinoma, Ovarian Epithelial 80Recurrence 75Squamous Cell Carcinoma of Head and Neck 74

Interventions

olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Ovarian × Genitourinary × Clear all
NCT01078662 2025-08-13

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

AstraZeneca

Phase 2 Completed
298 enrolled 18 charts
BreastGastrointestinalGenitourinaryGynecologic

Ovarian

Data powered by HemOnc (CC BY 4.0) Colophon âš¡